Analyst, Research and Markets has reported that the vaccine market size of China reached $2.3 billion (RMB15.2 billion) in 2009. The company has added "China Vaccine Industry Report, 2009-2010" report to their offering.

According to Research and Markets, China is not only the world's largest vaccine producers, but also has many vaccine companies, various vaccine categories and large quantity and even human and animal vaccine enterprises. At the end of 2009, there were around 38 human vaccine manufacturers and 54 animal vaccine producers that had passed CMP certification in China. With the development of national economy and the peoples growing awareness of precautionary measures, Chinese vaccine market scale had increased continuously, with a CAGR of 21.5 percent during 2007-2009. Out of the market size of $2.3 billion, around $1.4 billion (RMB 9 billion) of human vaccine and $933 million (RMB6.2 billion) or so of animal vaccine were included.

The vaccine industry is said to be featured by high investment, high risk, long cycle and high profit. In spite of somewhat drop in profit in recent years due to increasingly intensive market competition, the overall profitability of the vaccine industry is still kept at a relatively high level thanks to the lower risk of disorderly competition as well as the restriction of barriers like policy, technology and capital. In 2009, the gross margin of animal vaccine industry was over 60 percent, and that of human vaccine industry was higher, above 70 percent.

In fact, the compulsory and free EPI vaccines are dominant in inoculation vaccines in China on account of relatively low economic level and comparatively lower awareness of epidemic precaution. Taking human vaccine market for example, the release of EPI human vaccines reached 648.4261 million person doses in 2009, accounting for 80.4 percent of the total; while the extra EPI vaccine was only 158.512 million person doses, with a share of 19.6 percent. Yet, the sum of EPI vaccine only occupied 38.9 percent of the total being restricted by governmental procurement price, while the extra EPI vaccine covered 61.1 percent.

Focusing upon the overall vaccine market of China, the report also delves into the development status quo, market scale, market demand & supply, competition pattern, import & export, development prospect and relevant companies of human vaccine and animal vaccine market segments.